Want to join the conversation?
Biotechnology company $TMO signed an agreement with $NVS & $PFE to develop & commercialize a next-generation sequencing (NGS) oncology test as a companion diagnostic for non-small cell lung cancer. The NGS-based companion diagnostic test will be developed using $TMO's Ion PGM Dx System and Oncomine assays.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.